Complement and cytokine based therapeutic strategies in myasthenia gravis
- 30 September 2011
- journal article
- review article
- Published by Elsevier BV in Journal of Autoimmunity
- Vol. 37 (2), 136-143
- https://doi.org/10.1016/j.jaut.2011.05.006
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- Update on the genetics and genomics of PBCJournal of Autoimmunity, 2010
- Light, including ultravioletJournal of Autoimmunity, 2010
- Autoimmune thyroiditis: A model uniquely suited to probe regulatory T cell functionJournal of Autoimmunity, 2009
- Sjögren syndrome: Advances in the pathogenesis from animal modelsJournal of Autoimmunity, 2009
- A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravisGenes & Immunity, 2009
- Novel complement inhibitor limits severity of experimentally myasthenia gravisAnnals of Neurology, 2009
- IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†Brain, 2008
- C5a is not involved in experimental autoimmune myasthenia gravis pathogenesisJournal of Neuroimmunology, 2008
- The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in miceClinical and Experimental Immunology, 2006
- Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis ratsClinical and Experimental Immunology, 2006